Thompson Siegel & Walmsley LLC Sells 1,124 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Thompson Siegel & Walmsley LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,490 shares of the biopharmaceutical company's stock after selling 1,124 shares during the quarter. Thompson Siegel & Walmsley LLC's holdings in Regeneron Pharmaceuticals were worth $7,874,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of REGN. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 19 shares during the period. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $26,000. Sachetta LLC grew its position in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth $28,000. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at about $33,000. Institutional investors own 83.31% of the company's stock.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $6.50 during trading hours on Friday, hitting $738.00. 1,029,423 shares of the company traded hands, compared to its average volume of 539,322. Regeneron Pharmaceuticals, Inc. has a 1-year low of $735.95 and a 1-year high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm's 50-day simple moving average is $945.07 and its two-hundred day simple moving average is $1,026.63. The firm has a market cap of $81.10 billion, a P/E ratio of 18.26, a P/E/G ratio of 2.81 and a beta of 0.15.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on REGN. Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a research note on Friday, November 1st. Oppenheimer reduced their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. Barclays cut their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. Finally, Citigroup started coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a "neutral" rating and a $895.00 target price on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.